抗血管生成在小细胞肺癌治疗中的研究进展

Advances in anti-angiogenesis in the treatment of small cell lung cancer

小细胞肺癌是一种具有高度侵袭性的恶性肿瘤。虽然其对放化疗敏感程度高,但易发生复发转移,对于放化疗进展后的小细胞肺癌,目前尚缺乏有效的治疗手段,广泛期患者的总生存期不到一年,因此迫切需要探索一种具体有效的新药。目前,靶向治疗已引起人们的关注,抗血管生成药物通过阻断肿瘤生长所需的血管,已经在几种恶性肿瘤中有了证实的疗效,为目前小细胞肺癌的治疗提供了新的思路。同时,鉴于最近免疫疗法的成功,抗血管生成药物与免疫检查点阻断剂的组合也已成为值得研究的治疗方式。本文通过探讨抗血管生成药物的研究进展,以及联合免疫治疗取得的成果,以期对小细胞肺癌的治疗提供一些参考。

Small cell lung cancer is a highly invasivemalignancy.Although it is highly sensitive to radiotherapy and chemotherapy,it is prone to recurrence or metastasis.There is no effective treatment for a recurrence after the radiotherapy and chemotherapy.The overall survival of extensive patients is less than one year.So it’s urgent to find a concrete and effective new drug.At present,targeted therapy has captured our attention.Anti-angiogenic drugs have beem proven to be effective in several cancer by blocking the blood that tumors need to grow.And it provides a new way to cure small cell lung cancer.Meanwhile anti-angiogenesis combined with immune checkpoint inhibitors has become a treatment worthy to study due to its success of immunotherapy.This article hopes to provide some references for the treatment of small cell lung cancer by discussing the advances of anti-angiogenesis and combined immunotherapy.